

Coagulation Treatment / BPA

Reference Number: RDF1931-23

Date of Response: 20/10/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear FOI team,

I would like to submit an FOI request for the following coagulation factors product:

- How many patients did you treat with Bypassing agents (BPA)/Hemlibra inhibitor in Q3'23 (July, August, September 2023)?*

Answer: The Trust does not hold this information in a reportable dataset and cannot provide an accurate response.

- With BPA/Hemlibra Inhibitor?*

Answer: Please see response to question 1.

- Please fill in the BPA/Hemlibra products utilized in July, August, and September 2023.*

July 1st through September 2023		Q3'23 Volume (IU)/mg		Total Patients	Patients	
					Prophylaxis	On demand
	<i>Example: FEIBA</i>	50,000 IU		1	0	0
Hem A Inhibitor Patients						
<i>Haem A Inhibitor Patients</i>	<i>FEIBA</i>					
	<i>Cevenfacta</i>					
	<i>NovoSeven</i>					
	<i>Hemlibra</i>					
Hem B Inhibitor Patients						
<i>Haem B Inhibitor Patients</i>	<i>FEIBA</i>					
	<i>Cevenfacta</i>					
	<i>NovoSeven</i>					
	<i>Obizur</i>					
AHA Patients						
<i>AHA Patients</i>	<i>FEIBA</i>					
	<i>NovoSeven</i>					
	<i>Obizur</i>					
	<i>Cevenfacta</i>					

	<i>Hemlibra</i>					
<i>FVII deficient</i>	<i>NovoSeven</i>					
<i>Glanzmann's</i>	<i>NovoSeven</i>					
<i>Other</i>	<i>NovoSeven</i>					
<i>Other</i>	<i>Cevenfacta</i>					

Answer: Please see response to question 1.

3. How **many** minor and major surgeries did your BPA patients have in July, August, and September 2023? (By minor surgeries, we imply minimally invasive surgical procedures)

	<i>Inhibitor patients</i>		<i>Glanzmann, FVII deficiency, AHA</i>	
	<i>Minor surgeries</i>	<i>Major surgeries</i>	<i>Minor surgeries</i>	<i>Major surgeries</i>
<i>NovoSeven</i>				
<i>FEIBA</i>				
<i>Obizur</i>				

Answer: Please see response to question 1.

4. How **many** minor and major surgeries did your BPA/Hemlibra inhibitor patients have in July, August, and September 2023?? (By Major surgeries: implies invasive surgical procedures, including but not limited to hip and knee replacement surgeries)

	<i>Inhibitor patients</i>		<i>Glanzmann, FVII deficiency, AHA</i>	
	<i>Minor surgeries</i>	<i>Major surgeries</i>	<i>Minor surgeries</i>	<i>Major surgeries</i>
<i>NovoSeven</i>				
<i>FEIBA</i>				
<i>Obizur</i>				

Answer: Please see response to question 1.

5. How many **breakthrough bleeds** did your Hemlibra Inhibitor patients have, and what brand were they treated with?

	<i>Inhibitor patients</i>	<i>Q3'23 volume (IU/mg)</i>
<i>Hemlibra</i>		
<i>NovoSeven</i>		
<i>FEIBA</i>		

Answer: Please see response to question 1.

6. Were there any changes in the total number of acute bleeds treated with factor in Q3'23 as compared to Q2'23?

Answer: Please see response to question 1.

7. Was there any change in the number of elective surgeries **using factor** in Q3'23 as compared to Q2'23?

Number of Surgeries	BPA
Increase / Decrease / Stable compared to Q2'23?	
How many surgeries occurred in Q3'23?	

Answer: Please see response to question 1.

8. Have any BPA patients switched products between July 1st through September 30th 2023? What were the reasons for the switches?

Answer: Please see response to question 1.

Indication	Previous Medication	Previous Regimen	Current Medication	Current Regimen	Severity of patient	Reason
Example: Haem B Inh.	1 NovoSeven	On- demand	Cevenfacta	Prophy 1x/week	Severe	Patient requested to try out a new product to improve treatment

Answer: Please see response to question 1.

9. What is the total number of patients treated with NovoSeven at your center?

Answer: Please see response to question 1.